Hi Lef, cheers mate.
Regarding the comparison, I was more so pointing out that various rerates can occur long before commercialization or even reg approval stage as shown with others, RAP is a good example and was a good performer in med tech space, not so much saying they're comparable companies or same field etc
I wouldn't imagine many denying the amazing value EMV represents.
EMvision Research Notes, page-3
-
- There are more pages in this discussion • 2,560 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.16 |
Change
-0.130(5.68%) |
Mkt cap ! $184.5M | |||
| Open | High | Low | Value | Volume |
| $2.28 | $2.29 | $2.15 | $73.74K | 33.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1449 | $2.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.30 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| EMV (ASX) Chart |